It has been reported that the number of Lox-1+ PMN-MDSCs in nonresponders is significantly higher than that in responders after the 1st nivolumab treatment and that related factors involved in MDSC proliferation (CXCL2, CCL23, and CX3CL1) and recruitment (HMGB1) exhibit the same trend, suggesting that Lox-1+ PMN-MDSCs are a specific subset with immunosuppressive function in NSCLC patients. Here, OLR1 is linked to non-small cell lung carcinoma.